Compare KELYB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | NGNE |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.7M | 744.9M |
| IPO Year | 1994 | 2014 |
| Metric | KELYB | NGNE |
|---|---|---|
| Price | $22.67 | $23.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $77.88 |
| AVG Volume (30 Days) | 8.6K | ★ 354.4K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $150.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.38 | $15.93 |
| 52 Week High | $125.00 | $43.66 |
| Indicator | KELYB | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 33.35 |
| Support Level | $21.75 | $16.88 |
| Resistance Level | $24.77 | $23.35 |
| Average True Range (ATR) | 0.55 | 1.99 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 50.76 | 26.52 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.